279 related articles for article (PubMed ID: 15822043)
1. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
Tsujino T; Komatsu Y; Isayama H; Hirano K; Sasahira N; Yamamoto N; Toda N; Ito Y; Nakai Y; Tada M; Matsumura M; Yoshida H; Kawabe T; Shiratori Y; Omata M
Clin Gastroenterol Hepatol; 2005 Apr; 3(4):376-83. PubMed ID: 15822043
[TBL] [Abstract][Full Text] [Related]
2. The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
Tsujino T; Isayama H; Nakai Y; Ito Y; Togawa O; Toda N; Arizumi T; Kogure H; Yamamoto K; Mizuno S; Yashima Y; Yagioka H; Sasaki T; Matsubara S; Yamamoto N; Hirano K; Sasahira N; Tada M; Koike K
J Gastroenterol; 2013 Aug; 48(8):982-8. PubMed ID: 23090004
[TBL] [Abstract][Full Text] [Related]
3. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.
Yoo JW; Ryu JK; Lee SH; Woo SM; Park JK; Yoon WJ; Lee JK; Lee KH; Hwang JH; Kim YT; Yoon YB
Pancreas; 2008 Nov; 37(4):366-70. PubMed ID: 18953247
[TBL] [Abstract][Full Text] [Related]
5. Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Uchino R; Isayama H; Tsujino T; Sasahira N; Ito Y; Matsubara S; Takahara N; Arizumi T; Toda N; Mohri D; Togawa O; Yagioka H; Yanagihara Y; Nakajima K; Akiyama D; Hamada T; Miyabayashi K; Mizuno S; Kawakubo K; Kogure H; Sasaki T; Yamamoto N; Nakai Y; Hirano K; Tada M; Koike K
Gastrointest Endosc; 2013 Dec; 78(6):842-850. PubMed ID: 23910063
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, double-blind, placebo-controlled trial of ulinastatin for prevention of hyperenzymemia after double balloon endoscopy via the antegrade approach.
Itaba S; Nakamura K; Aso A; Tokunaga S; Akiho H; Ihara E; Iboshi Y; Iwasa T; Akahoshi K; Ito T; Takayanagi R
Dig Endosc; 2013 Jul; 25(4):421-7. PubMed ID: 23368820
[TBL] [Abstract][Full Text] [Related]
7. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
[TBL] [Abstract][Full Text] [Related]
9. Antiproteases in preventing post-ERCP acute pancreatitis.
Tsujino T; Kawabe T; Omata M
JOP; 2007 Jul; 8(4 Suppl):509-17. PubMed ID: 17625308
[TBL] [Abstract][Full Text] [Related]
10. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
[TBL] [Abstract][Full Text] [Related]
11. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
[TBL] [Abstract][Full Text] [Related]
12. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp?
Chen S; Shi H; Zou X; Luo H
Pancreas; 2010 Nov; 39(8):1231-7. PubMed ID: 20531245
[TBL] [Abstract][Full Text] [Related]
13. Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial.
Fogel EL; Lehman GA; Tarnasky P; Cote GA; Schmidt SE; Waljee AK; Higgins PDR; Watkins JL; Sherman S; Kwon RSY; Elta GH; Easler JJ; Pleskow DK; Scheiman JM; El Hajj II; Guda NM; Gromski MA; McHenry L; Arol S; Korsnes S; Suarez AL; Spitzer R; Miller M; Hofbauer M; Elmunzer BJ;
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):132-141. PubMed ID: 31780277
[TBL] [Abstract][Full Text] [Related]
14. A randomized control study to investigate the application of Ulinastatin-containing contrast medium to prevent post-ERCP pancreatitis.
Wang J; Su J; Lu Y; Zhou H; Gong B
Hepatogastroenterology; 2014; 61(136):2391-4. PubMed ID: 25699389
[TBL] [Abstract][Full Text] [Related]
15. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
16. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial.
Poon RT; Yeung C; Liu CL; Lam CM; Yuen WK; Lo CM; Tang A; Fan ST
Gut; 2003 Dec; 52(12):1768-73. PubMed ID: 14633959
[TBL] [Abstract][Full Text] [Related]
17. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence.
van Westerloo DJ; Rauws EA; Hommes D; de Vos AF; van der Poll T; Powers BL; Fockens P; Dijkgraaf MG; Bruno MJ
Gastrointest Endosc; 2008 Aug; 68(2):246-54. PubMed ID: 18455169
[TBL] [Abstract][Full Text] [Related]
18. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V
N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777
[TBL] [Abstract][Full Text] [Related]
19. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
Sherman S; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Earle D; Temkit M; Lehman GA
Gastrointest Endosc; 2003 Jul; 58(1):23-9. PubMed ID: 12838216
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
